Fangxin Hong

Senior Research Scientist
This email address is being protected from spambots. You need JavaScript enabled to view it.



Dr. Hong has worked primarily on the design, monitoring analysis of cancer clinical trials and randomized control trials.  She serves as the lead statistician for the Eastern Cooperative Oncology Group's Lymphoma Committee, and for the nursing and patient care research at Dana-Farber Cancer Institute.  Her current research work focuses on the design of phase II and phase III clinical trials incorporating predictive biomarkers, developing predictive molecular signatures from gene array data, and methods on patient outcome data analysis.



Dr. Hong received her PhD from University of California, Davis in 2004 and then served as a bioinformatician as the Salk Institute for Biological Sciences.  Later she was an Assistant Professor at the City of Hope National Medical Center, and in 2007, joined DFCI.  She also works at the statistical office for the Eastern Cooperative Oncology Group.  In year 2012, she was a guest researcher at the Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute.


Recent Publications

Del Carratore F, Jankevics A, Eisinga R, Heskes T, Hong F, Breitling R.
RankProd 2.0: a refactored Bioconductor package for detecting differentially
expressed features in molecular profiling datasets. Bioinformatics. 2017 May 8.


Hong F, Blonquist TM, Halpenny B, Berry DL. Patient-reported symptom distress,
and most bothersome issues, before and during cancer treatment. Patient Relat
Outcome Meas. 2016 Sep 12;7:127-35.


Fann JR, Hong F, Halpenny B, Blonquist TM, Berry DL. Psychosocial outcomes of
an electronic self-report assessment and self-care intervention for patients with
cancer: a randomized controlled trial. Psychooncology. 2016 Aug 17.


Barta SK, Li H, Hochster HS, Hong F, Weller E, Gascoyne RD, Habermann TM,
Gordon LI, Colocci N, Bengtson EM, Horning SJ, Kahl BS. Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer. 2016 Oct;122(19):2996-3004.


Schiff D, Hong F, Alexander B. Defining optimal initial therapy for primary
CNS lymphoma. Lancet Haematol. 2016 May;3(5):e206-7.


Siefert ML, Bonquist TM, Berry DL, Hong F. Symptom-related emergency
department visits and hospital admissions during ambulatory cancer treatment. J
Community Support Oncol. 2015 May;13(5):188-94.


Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016 Jun;173(6):867-75.


Berry DL, Blonquist TM, Hong F, Halpenny B, Partridge AH. Self-reported
adherence to oral cancer therapy: relationships with symptom distress,
depression, and personal characteristics. Patient Prefer Adherence. 2015 Nov


Kenkre VP, Hong F, Cerhan JR, Lewis M, Sullivan L, Williams ME, Gascoyne RD,
Horning SJ, Kahl BS. Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. Clin Cancer Res. 2016 Feb 15;22(4):821-6.


Maurer MJ, Jais JP, Ghesquières H, Witzig TE, Hong F, Haioun C, Thompson CA,
Thieblemont C, Micallef IN, Porrata LF, Ribrag V, Nowakowski GS, Casasnovas O,
Bologna S, Morschhauser F, Morrison VA, Peterson BA, Macon WR, Copie-Bergman C, Feldman AL, Syrbu SI, Kurtin PJ, Gascoyne RD, Li H, Allmer C, Kahl BS, Ansell SM, Slager SL, Link BK, Salles G, Habermann TM, Tilly H, Cerhan JR. Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. Am J Hematol. 2016 Feb;91(2):179-84.




Related Links